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VEGFa b s t r a c t
Lysophosphatidic acid (LPA) is a lipid growth factor with multiple biological functions and has been
shown to stimulate cancer cell secretion of vascular endothelial growth factor-A (VEGF-A) and trigger
angiogenesis. Hypoxia-inducible factor-1 (HIF-1), a heterodimer consisting of HIF-1a and HIF-1b (also
known as aromatic hydrocarbon receptor nuclear translocator (ARNT)) subunits, is an important regula-
tor of angiogenesis in prostate cancer (PC) through the enhancement of VEGF-A expression. In this study,
we ﬁrst conﬁrmed the ability of LPA to induce VEGF-A expression in PC-3 cells and then validated that
LPA-induced VEGF-A expression was regulated by HIF-1a and ARNT through phosphatidylinositol 3-
kinase activation. Aromatic hydrocarbon receptor (AHR), a receptor for dioxin-like compounds, functions
as a transcription factor through dimerization with ARNT and was found to inhibit prostate carcinogen-
esis and vanadate-induced VEGF-A production. Since ARNT is a common dimerization partner of AHR and
HIF-1a, we hypothesized that AHR might suppress LPA-induced VEGF-A expression in PC-3 cells by com-
peting with HIF-1a for ARNT. Here we demonstrated that overexpression and ligand activation of AHR
inhibited HIF-1-mediated VEGF-A induction by LPA treatment of PC-3 cells. In conclusion, our results sug-
gested that AHR activation may inhibit LPA-induced VEGF-A expression in PC-3 cells by attenuating HIF-
1a signaling, and subsequently, suppressing angiogenesis and metastasis of PC. These results suggested
that AHR presents a potential therapeutic target for the prevention of PC metastasis.
 2013 The Authors. Published by Elsevier Inc. Open access under CC BY-NC-SA license.1. Introduction
Prostate cancer (PC) is the most frequently diagnosed cancer
and second leading cause of cancer death in American men [1]. It
usually originates as an uncontrolled and abnormal growth within
the glandular tissue of the prostate gland, which is referred to as
prostatic adenocarcinoma. Androgens are the main regulators of
PC growth and survival by both stimulating cellular proliferation
and inhibiting apoptosis [2]. Hormone therapy for androgen depri-
vation or ablation can effectively slow or inhibit PC proliferation
[3]. Although hormone therapy can temporarily successfullycontrol PC progression, PC often relapses, transforms to an andro-
gen refractory tumor or androgen-independent cell-type, and be-
comes more aggressive and metastatic [4,5].
Lysophosphatidic acid (LPA) is a bioactive lysophospholipid that
affects diverse cellular and pathological processes, such as cell pro-
liferation and cancer progression [6,7], and is mainly stored in
platelets and released upon an inﬂammatory response. The esti-
mated concentrations of active, albumin-bound LPA in normal hu-
man serum are within the range of 1–5 lM [8]; however, in cancer
patients, serum levels may increase to 80 lM [9]. LPA binds to a
family of G protein-coupled receptors, termed LPA1–LPA5, to regu-
late cellular functions [10]. In PC, LPA regulates cancer cell prolifer-
ation, migration, invasion, and survival [11–14]. Moreover, LPA is
known to stimulate cancer cells to secret vascular endothelial
growth factor-A (VEGF-A) and trigger angiogenesis.
Hypoxia-inducible factor 1 (HIF-1) is a heterodimer consisting
of two subunits: HIF-1a and HIF-1b, which is also known as aryl
hydrocarbon receptor nuclear translocator (ARNT) [15]. HIF-1a is
tightly regulated in response to hypoxia [15] and signiﬁcantly
overexpressed in PC [16]. Furthermore, HIF-1 was shown to
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These results strongly suggest that LPA stimulates VEGF-A produc-
tion, and therefore, induces angiogenesis through HIF-1 signaling
pathways in PC cells.
The aromatic hydrocarbon receptor (AHR) is a member of the
basic helix-loop-helix/per-arnt-sim family of transcription factors.
AHR binds to a wide variety of chemicals and is activated by the
environmental contaminant 2,3,7,8-tetrachlorodibenzo-p-dioxin
(TCDD), which leads to AHR nuclear localization, heterodimeriza-
tion with ARNT [15], and subsequent binding to aryl hydrocarbon
receptor enhancer elements located in the promoters of AHR-
responsive genes. Reportedly, AHR and ARNT might regulate the
carcinogenic process of PC [18,19]. Recent reports further sug-
gested that AHR inhibits prostate carcinogenesis and VEGF-A pro-
duction in transgenic adenocarcinoma of the mouse prostate
(TRAMP) [20,21]. Since ARNT is a common dimerization partner
of AHR and HIF-1a, it was hypothesized that AHR signaling may
suppress VEGF-A expression by competing with HIF-1a for ARNT,
thereby inhibiting angiogenesis and tumor growth in PCs. The
aim of this study was to determine whether AHR could sequester
ARNT from HIF-1a and subsequently reduce VEGF-A expression
in PC-3 cells.2. Materials and methods
2.1. Cell culture
The human PC-3 cell line was purchased from the American
Type Culture Collection (ATCC; Manassas, VA) and maintained in
RPMI-1640 medium supplemented with 10% FBS. Cell cultures
were incubated at 37 C in a humidiﬁed atmosphere of 5% CO2.2.2. Lentiviral production and transduction
To package the viruses, 293T cells were co-transfected with
7.5 lg of pLKO.1 lentiviral vectors, 1.9 lg of the envelope plasmid
pMD.G, and 5.6 lg of the packaging plasmid pCMVDR8.91. Viral
solutions were collected 24 and 48 h after transfection and con-
densed using PEG8000 solution. The viral titer was determined be-
fore use. For transduction, an appropriate volume of the viral
solution was combined with PC-3 cells in growth medium, which
was replaced after 24 h of incubation. Then, 48 h after viral trans-
duction, total RNA was extracted and subjected to real-time PCR.2.3. LPA stimulation
LPA (Sigma–Aldrich, St. Louis, MO, USA) was prepared in chloro-
form and methanol (1:9) and stored at 20 C. The PC-3 cells were
cultured to 70–80% conﬂuence in 9.5-cm2 wells with complete
medium, washed with PBS, and starved in serum-free RPMI-1640
medium for 16 h. After starvation, LPA was added into serum-free
RPMI-1640 culture medium with 0.005% fatty acid-free bovine ser-
um albumin as a carrier.2.4. RNA isolation and reverse transcription
Total RNA was isolated from PC-3 cells using the TRIzol reagent
(Invitrogen Corp., Carlsbad, CA, USA) according to the manufac-
turer’s protocol. The reverse transcription of isolated total RNA
(1 lg) was performed in a 20-lL reaction mixture containing
M-MuLV reverse transcriptase (Thermo Fisher Scientiﬁc, Waltham,
MA, USA) and oligo-dT primers.2.5. Real-time PCR
Real-time PCR was performed using the iCycler iQ Real-Time
detection system (Bio-Rad, Hercules, CA, USA) with SYBR Green I
as the ﬂuorescent dye, which enabled real-time detection of PCR
products. cDNA was real-time PCR-ampliﬁed using the primer
pairs listed below under cycling conditions of 95 C for 3 min, fol-
lowed by 40 cycles of 95 C for 30 s, 60 C for 30 s, and 72 C for
60 s. For quantiﬁcation, the target gene was normalized to the
internal standard gene glyceraldehyde-3-phosphate dehydroge-
nase (GAPDH) and the fold increase between the control and treat-
ment groups was calculated using the following equation: increase
fold = 2(CTT  CTS) of Tr  (CTT  CTS) of Co, where CTT is the
threshold cycle of the target gene, CTS is the threshold cycle of
the standard gene, Co represents the control groups, and Tr repre-
sents the treatment groups. Oligonucleotide primers for PCR were
designed using Beacon Designer2 software (Premier Biosoft Inter-
national, Palo Alto, CA, USA). cDNA was then subjected to PCR
ampliﬁcation with the following primer sets for AHR, ARNT, HIF-
1a, VEGF-A, and GAPDH: AHR forward, 50-TCC CCA TAC CCC ACT
ACT TC-30; AHR reverse, 50-GCT TGG AAT TAC AGG AAT CCA C-30;
ARNT forward, 50-GGA ACA AGA TGA CAG CCT AC-30; ARNT reverse,
50-CAG AAA GCC ATC TGC TGC C-30; HIF-1a forward, 50-TCC ATG
TGA CCA TGA GGA AA-30; HIF-1a reverse, 50-TAT CCA GGC TGT
GTC GAC TG-30; VEGF-A forward, 50-CTA CCT CCA CCA TGC CAA
GT-30; VEGF-A reverse, 50-ATC TGC ATG GTG ATG TTG GA-30; GAP-
DH forward, 50-CAT CTT CCA GGA GCG AGA-30; and GAPDH reverse,
50-CTG CTT CAC CAC CTT CTT GAT-30.
2.5.1. Statistical analysis
Data were analyzed for statistical signiﬁcance by one-way anal-
ysis of variance followed by the Fisher’s protected least-signiﬁcant
difference test using StatView software (Abacus Concept, Berkeley,
CA, USA). Each result was obtained from at least three independent
experiments and expressed as mean ± standard deviation. p < 0.05
was considered statistically signiﬁcant for all tests.3. Results
3.1. HIF-1a is required in LPA-induced VEGF-A expression
Previous studies have suggested that LPA stimulates VEGF-A
expression in PC cells [22,23]. In this study, we further conﬁrmed
that 5 lM LPA efﬁciently up-regulated VEGF-A mRNA expression
in PC-3 cells (Fig. 1B). VEGF-A is one of the best-characterized tar-
get genes regulated by HIF-1a [23]; therefore, we used RNA inter-
ference as a strategy to determine whether HIF-1a mediates LPA-
induced VEGF-A expression in PC-3 cells. Brieﬂy, PC-3 cells were
transduced with lentiviral control vectors or lentiviral HIF-1a
shRNA and then incubated with LPA. Total RNA was isolated, sub-
jected to real-time PCR to analyze mRNA expression, and then re-
verse-transcribed into cDNA. As shown in Fig. 1A, HIF-1a shRNA
transduced using the lentiviral system signiﬁcantly suppressed
HIF-1a mRNA expression. Moreover, LPA-induced VEGF-A mRNA
expression was blocked by HIF-1a shRNA (Fig. 1B). These results
strongly suggested that HIF-1a was required for LPA-induced
VEGF-A expression.
3.2. HIF-1b (ARNT) is required in LPA-induced VEGF-A expression
HIF-1b (ARNT) was suggested as an essential dimerization part-
ner of HIF-1a to form the HIF-1 complex, which acts as a transcrip-
tion factor to regulate VEGF-A expression under hypoxic
conditions [24]. Under LPA stimulation, we found that HIF-1a
was required in the regulation of VEGF-A expression. Therefore,
Fig. 1. The role of HIF-1a in LPA-induced VEGF-A expression in PC-3 cells. (A) PC-3 cells were transfected with HIF-1a shRNA or a control vector for 48 h. The relative HIF-1a
mRNA levels were measured by real-time PCR. (B) After HIF-1a shRNA transfection, cells were starved for 12 h and then incubated with 5 lM of LPA or methanol–chloroform
for 2 h. The relative mRNA levels of VEGF-A were analyzed using real-time PCR. ⁄p < 0.05; ⁄⁄⁄p < 0.005.
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mine whether HIF-1b (ARNT) regulated LPA-induced VEGF-A
expression. Real-time PCR analysis showed that HIF-1b (ARNT)
shRNA efﬁciently suppressed HIF-1b (ARNT) expression (Fig. 2A)
and subsequently inhibited LPA-induced VEGF-A mRNA transcrip-
tion (Fig. 2B). In contrast, LPA-induced VEGF-A expression was fur-
ther enhanced by HIF-1b (ARNT) overexpression (Fig. 2D). These
results demonstrated that HIF-1b (ARNT) was an important factor
in regulation of LPA-induced VEGF-A expression in PC-3 cells.
3.3. Phosphatidylinositol 3-kinase (PI3K) regulation of HIF-1a and
LPA-induced VEGF-A expression
Our results demonstrated that both components of the HIF-1
complex (HIF-1a and HIF-1b) were involved in the regulation of
LPA-induced VEGF-A expression and previous reports suggested
that PI3K may act as an upstream regulator of HIF-1a expression
in PC cells [25–30]. Furthermore, PI3K has been suggested to medi-
ate the effect of LPA in several cancers [31–33]. Therefore, we
hypothesized that PI3K signaling was required for HIF-1-mediated
VEGF-A expression in PC-3 cells. To determine whether PI3K sig-
naling mediates LPA-induced HIF-1a expression in PC-3 cells, ser-
um-starved cells were pretreated with either dimethyl sulfoxide
(DMSO) or 10 lM LY294002, a potent inhibitor of P13K, and then
treated with LPA. HIF-1a expression was then subjected to real-
time PCR. As shown in Fig. 3A, LY294002 inhibited LPA-induced
HIF-1a expression, which suggested that PI3K was required for
LPA-induced HIF-1a expression. Moreover, LPA-induced VEGF-A
expression was also signiﬁcantly suppressed by blockage of PI3K
activity (Fig. 3B). These results suggested that PI3K was an up-
stream regulator of HIF-1a signaling and mediated LPA-induced
VEGF-A expression.
3.4. Activation of AHR inhibits LPA-induced VEGF-A expression in PC-3
cells
AHR was previously reported to participate in inhibition of van-
adate-induced VEGF-A production and prostate carcinogenesis
[20,21]. Herein, we attempted to determine whether AHR signaling
activation suppressed LPA-induced VEGF-A transcription in PC-3
cells. Using a lentiviral transduction system, we successfully
overexpressed human AHR in PC-3 cells (Fig. 4A). Ectopic AHR
expression elicited a ligand-independent effect and signiﬁcantlydiminished LPA-induced VEGF-A expression (Fig. 4B). Furthermore,
activation of the AHR signaling pathway by the AHR agonist 3-
methylcholanthrene (3-MC) also efﬁciently suppressed LPA-in-
duced VEGF-A mRNA expression (Fig. 4C). These results demon-
strated that activation of AHR signaling inhibited LPA-induced
VEGF-A expression in PC-3 cells.4. Discussion
LPA has been implicated in regulation of cell proliferation,
migration, invasion, and survival in PC [11–14]. In this study, we
demonstrated that LPA-induced VEGF-A expression was regulated
by HIF-1a, HIF-1b (ARNT), and PI3K in PC-3 cells, which plays roles
in angiogenesis in PC. LPA was suggested to promote PC progres-
sion. Although LPA was initially shown to be released by activated
platelets, more recent studies established that LPA is produced by a
wide variety of mammalian cells, including PC cells, which report-
edly serves as an autocrine/paracrine mediator to affect the func-
tions of both cancer and neighboring cells [34]. Thus, LPA-
induced VEGF-A expression might also act through autocrine/par-
acrine signaling to promote PC progression.
The HIF-1a protein has been indicated to degrade under norm-
oxic conditions by the ubiquitin–proteasome system, whereas
hypoxic conditions induced HIF-1a stabilization and transactiva-
tion [35,36]. Furthermore, HIF-1a has been indicated to dimerize
with HIF-1b (ARNT) to form the HIF-1 complex, which then acti-
vates VEGF-A expression by directly binding to the VEGF-A pro-
moter in response to hypoxic conditions [35]. These ﬁndings
suggested that HIF-1a and HIF-1b were involved in hypoxia-in-
duced VEGF-A expression. In the present study, we ﬁrst demon-
strated that LPA-induced VEGF-A expression was HIF-1a- and
HIF-1b-dependent. Reportedly, reactive oxygen species (ROS) med-
iated LPA-induced signaling [37]. ROS are generated under hypoxic
conditions and activate protective responses, including HIF activa-
tion, in diverse cell types [38–41]. Taken together, we speculated
that LPA might induce ROS production to activate HIF-1 signaling
and subsequently promote VEGF-A expression, similar to the hyp-
oxic response. However, the speciﬁc mechanism of LPA-induced
HIF-1 expression requires further investigations.
AHR is a ligand-activated transcription factor that requires het-
erodimerization with ARNT to function. ARNT is also a dimeriza-
tion partner of HIF-1a in hypoxia-induced signaling. Therefore,
Fig. 2. ARNT regulation of LPA-induced VEGF-A expression in PC-3 cells. (A) PC-3 cells were transfected with ARNT expression vectors or control vectors for 48 h using a
lentiviral transduction system. The relative ARNT mRNA expression levels were measured by real-time PCR. (B) After ARNT overexpression, the cells were starved for 24 h and
then incubated with 5 lM of LPA or methanol–chloroform. The relative VEGF-A mRNA expression levels were measured by real-time PCR. (C) PC-3 cells were transfected with
ARNT shRNA or control vector for 48 h using the lentiviral transduction system. The relative ARNT mRNA expression levels were measured by real-time PCR. (D) After ARNT
shRNA transfection, the cells were starved for 24 h and incubated with 5 lM of LPA or methanol–chloroform. The relative VEGF-A mRNA expression levels were measured by
real-time PCR. NS, non-signiﬁcant; ⁄⁄p < 0.01; ⁄⁄⁄p < 0.005.
Fig. 3. Effects of PI3K on LPA-induced HIF-1a and VEGF-A expression in PC-3 cells. (A) and (B) Serum-starved PC-3 cells were pretreated with 10 lM of LY294002 or the
solvent control DMSO for 1 h and then treated with 5 lM of LPA or methanol–chloroform for 2 h. The relative HIF-1a and VEGF-A mRNA expression levels were determined
by real-time PCR. NS, non-signiﬁcant; ⁄p < 0.05; ⁄⁄p < 0.01.
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Fig. 4. AHR overexpression and activation inhibits LPA-induced VEGF-A expression in PC-3 cells. (A) PC-3 cells were transduced with AHR expression vectors or control
vectors. AHR mRNA levels were measured by real-time PCR. (B) After viral transduction, cells were starved and then incubated with 5 lM LPA or methanol–chloroform as a
control. The relative VEGF-A mRNA expression levels were analyzed by real-time PCR. (C) Serum-starved PC-3 cells were pretreated with 1 lM of the selective AHR
modulator, 3-methylcholanthrene (3-MC), or the solvent control, DMSO, for 6 h and then treated with LPA or methanol–chloroform for 2 h. The relative VEGF-A mRNA
expression levels were determined by real-time PCR. NS, non-signiﬁcant;⁄p < 0.05; ⁄⁄⁄p < 0.005.
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Collectively, these results suggested that reciprocal crosstalk may
occur between AHR and hypoxia signaling pathways. Furthermore,
it was demonstrated that hypoxia inhibited AHR activity in an
ARNT-dependent manner in topminnow hepatocarcinoma cells
[42]. The hypoxic response was also suggested to decrease TCDD-
induced responses in zebraﬁsh embryos [43]. Reciprocally, ectopic
expression of constituted, activated, truncated AHR (CD553)
blocked hypoxia-induced signaling in breast cancer [44]. More-
over, the results in this study suggested that overexpression and li-
gand activation of AHR suppressed LPA-induced VEGF-A
expression, which is HIF-1a- and ARNT-dependent. Collectively,
this evidence supported the presence of crosstalk between ARNT-
dependent pathways. Therefore, activation of this ARNT-depen-
dent pathway may inhibit the activation of other pathways that
depend on ARNT. Here, we clearly demonstrated that AHR seques-
tered ARNT from HIF-1a in PC-3 cells and subsequently reduced
LPA-induced VEGF-A expression.
Vanadate is a potent mitogenic agent and was shown to induce
HIF-1 activation and VEGF-A production in DU145 human prostate
carcinoma cells [45]. AHR was suggested to sequester HIF-1b
(ARNT), thereby decreasing interaction with HIF-1a in the inhibi-
tion of vanadate-induced VEGF-A production in TRAMP prostates
[20]. Moreover, activation of AHR inhibits prostate tumor metasta-sis in TRAMPmice [46]. In our present study, we showed that over-
expression and activation of AHR inhibited LPA-induced VEGF-A
expression in PC-3 cells, suggesting a role of AHR as a tumor sup-
pressor in PC, similar to the effect previously reported in heart [47]
and breast cancers [48]. Therefore, AHR ligand treatment may be a
potential strategy for PC therapy. Reportedly, less toxic dioxin
alternatives were used to successfully hinder breast cancer pro-
gression [48]. These less toxic alternatives are collectively referred
to as selective AHR modulators (SAHRMs), which includes 3-MC
and 6-methyl-1,3,8-trichlorodibenzofuran. SAHRMs share the
common ability with dioxin to activate AHR signaling, but they
are distinguished from dioxin by their weakened toxicity [49]. In
addition to inhibiting proliferation of human LNCaP cells, SAHRMs
have been indicated to inhibit VEGF-A expression as well as to re-
duce pelvic lymph node metastasis in TRAMP mice [50]. It was also
shown in this study that one of the SAHRMs, 3-MC, efﬁciently
inhibited LPA-induced VEGF-A production. Thus, novel toxicity-
free SAHRMs warrant further exploration for future PC treatments.
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